2024-10-26 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**1. Performance Comparison:**

Johnson & Johnson (JNJ) has underperformed the S&P 500 (VOO) significantly over the period analyzed. While the S&P 500 generated a cumulative return of 135.48%, JNJ's return stands at 36.59%, resulting in a substantial gap of -98.89%. This underperformance is further highlighted by the relative divergence score of 5.74, placing JNJ in the lower percentile range when compared to the historical performance against the S&P 500.

**2. Recent Price Movement:**

JNJ's recent price movement indicates a relatively stable trend. 

* **Closing Price:** $163.67 (Last-market: $160.87)
* **5-day Moving Average:** $164.19
* **20-day Moving Average:** $162.23
* **60-day Moving Average:** $162.73

The stock price is currently above the 20-day and 60-day moving averages, suggesting potential upward momentum. However, it has dipped slightly from the 5-day moving average, indicating some short-term correction. 

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 61.95
* **PPO (Percentage Price Oscillator):** 0.2
* **Delta_Previous_Relative_Divergence:** +0.4 (Positive), indicating a short-term upward trend.
* **Expected Return:** 0.0%. This indicates that JNJ is expected to generate a similar return to the S&P 500 over the long term (2+ years) under current conditions.

**4. Recent Earnings and Outlook:**

**Recent Earnings:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |

**Analysis:**

JNJ's recent earnings performance shows fluctuations but generally remains stable. While the latest earnings report for Q3 2024 is not available, it is important to note that previous quarters have consistently exceeded analyst estimates. 

**5. News and Recent Issues:**

* **Earnings News:** To provide accurate and up-to-date news analysis, please provide specific dates for the required earnings news information. This will allow me to analyze relevant news sources like Shacknews and others to provide insights.
* **Recent Market Outlook:** JNJ, as a healthcare giant with a diversified portfolio, is generally considered a defensive stock. It's expected to be less volatile than the broader market. Recent market outlooks for JNJ are optimistic, pointing towards its consistent dividend payments and stable earnings. 
* **Analyst Opinions and Performance Highlights:** Analyst opinions on JNJ are generally positive. According to FINBOLD, JNJ's stock has a consensus rating of "Buy" with a price target of $180. Many analysts highlight JNJ's strong brand recognition, its diversified business model, and its robust cash flow as key strengths.

**6. Comprehensive Analysis:**

Johnson & Johnson (JNJ) currently exhibits a mixed performance. Although it significantly underperformed the S&P 500 in the past, its recent price action suggests potential upward momentum. Technical indicators paint a relatively positive picture, with the RSI indicating a healthy momentum and the PPO suggesting a slight positive bias. JNJ's earnings have been relatively stable, with a history of exceeding analyst estimates. However, further analysis of recent earnings announcements is needed to provide a more comprehensive overview. 

Overall, JNJ appears to be a stable and reliable stock with a strong track record. Investors looking for long-term growth and dividend income may find it attractive. However, its current underperformance compared to the S&P 500 and potential future market uncertainties should be taken into account. 

**7. Report (English):**

## Johnson & Johnson (JNJ) Stock Analysis

This report provides an analysis of Johnson & Johnson (JNJ) stock based on the provided data. 

**1. Performance Comparison:**

JNJ has significantly underperformed the S&P 500 (VOO) during the analyzed period. While the S&P 500 generated a 135.48% cumulative return, JNJ returned only 36.59%, resulting in a substantial gap of -98.89%. This underperformance is evident in the relative divergence score of 5.74, placing JNJ in the lower percentile range when compared to its historical performance against the S&P 500.

**2. Recent Price Movement:**

JNJ's recent price action exhibits a relatively stable trend. 

* **Closing Price:** $163.67 (Last-market: $160.87)
* **5-day Moving Average:** $164.19
* **20-day Moving Average:** $162.23
* **60-day Moving Average:** $162.73

The stock currently trades above the 20-day and 60-day moving averages, hinting at potential upward momentum. However, a slight dip from the 5-day moving average suggests some short-term correction. 

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 61.95
* **PPO (Percentage Price Oscillator):** 0.2
* **Delta_Previous_Relative_Divergence:** +0.4 (Positive), indicating a short-term upward trend.
* **Expected Return:** 0.0%.  This suggests that JNJ is expected to generate a similar return to the S&P 500 over the long term (2+ years) under current conditions.

**4. Recent Earnings and Outlook:**

**Recent Earnings:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |

**Analysis:**

JNJ's recent earnings performance shows fluctuations but generally remains stable. While the latest earnings report for Q3 2024 is not available, previous quarters have consistently exceeded analyst estimates. 

**5. News and Recent Issues:**

* **Earnings News:** To provide accurate and up-to-date news analysis, please provide specific dates for the required earnings news information. This will allow me to analyze relevant news sources like Shacknews and others to provide insights.
* **Recent Market Outlook:** JNJ, as a healthcare giant with a diversified portfolio, is generally considered a defensive stock. It's expected to be less volatile than the broader market. Recent market outlooks for JNJ are optimistic, pointing towards its consistent dividend payments and stable earnings. 
* **Analyst Opinions and Performance Highlights:** Analyst opinions on JNJ are generally positive. According to FINBOLD, JNJ's stock has a consensus rating of "Buy" with a price target of $180. Many analysts highlight JNJ's strong brand recognition, its diversified business model, and its robust cash flow as key strengths.

**6. Comprehensive Analysis:**

Johnson & Johnson (JNJ) currently exhibits a mixed performance. Although it significantly underperformed the S&P 500 in the past, its recent price action suggests potential upward momentum. Technical indicators paint a relatively positive picture, with the RSI indicating a healthy momentum and the PPO suggesting a slight positive bias. JNJ's earnings have been relatively stable, with a history of exceeding analyst estimates. However, further analysis of recent earnings announcements is needed to provide a more comprehensive overview. 

Overall, JNJ appears to be a stable and reliable stock with a strong track record. Investors seeking long-term growth and dividend income may find it attractive. However, its current underperformance compared to the S&P 500 and potential future market uncertainties should be taken into account. 
